Business Context and Reporting Period
This Form 6-K filing by GSK plc (GSK) covers the month of May 2026. The document serves as a notification of a major holding change pursuant to UK Disclosure and Transparency Rules (DTR), rather than a financial performance report.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory notification regarding shareholder ownership thresholds.
Material Changes
The material change reported is an acquisition of voting rights by the institutional investor Dodge & Cox. As of April 28, 2026, Dodge & Cox crossed a notifiable threshold, resulting in a total holding of 4.93% of GSK's voting rights.
- Total Voting Rights Held: 200,296,898 shares
- Percentage of Voting Rights: 4.93%
- Composition:
- Ordinary Shares (ISIN GB00BN7SWP63): 88,958,040 shares (2.19%)
- ADRs (ISIN US37733W2044): 111,338,858 shares (2.74%)
- Financial Instruments: 0.00% (No voting rights held through financial instruments)
Guidance, Outlook, and Risks
The filing text does not provide a clear value for management guidance, outlook, commentary, risks, contingencies, or unusual items. The document contains no forward-looking statements regarding GSK's business operations.
Investor Verification Checklist
- Verify the exact date the 4.93% threshold was crossed (April 28, 2026).
- Confirm the split between direct holdings in Ordinary Shares versus ADRs.
- Check subsequent filings to determine if Dodge & Cox intends to increase its stake further or if this represents a stable position.
- Review GSK's most recent Form 20-F for actual financial performance data, as this 6-K contains none.